OBJECTIVE： To evaluate the cost and utility of ivabradine in the treatment of chronic heart failure （CHF） patients in China. METHODS： The cost and utility of standard plan plus ivabradine （called “ivabradine plan” for short） vs. standard plan were evaluated by Markov model， and lifetime total costs and quality adjusted life years （QALYs） were obtained. The clinical parameters were obtained from SHIFT China subgroup study； cost and utility data related to CHF came from domestic published literatures. Single-factor sensitivity analysis and probability sensitivity analysis were performed to test cost-utility analysis. RESULTS： Compared with standard plan， ivabradine plan could increase 0.30 QALYs； at the same time， the total cost increased by 20 153.70 yuan， and the incremental cost-utility ratio was 67 189.50 yuan/QALY. Probability sensitivity analysis showed that the probability of ivabradine plan with cost and utility was 90％ when pay threshold was 3 times GDP per capita （140 000 yuan/QALY）. The cardiovascular mortality risk ratio of ivabradine plan to standard plan was most sensitive model parameters. CONCLUSIONS： Compared with standard plan， additional use of ivabradine in the therapy for China CHF patients shows cost and utility.